1. Home
  2. PK vs AMLX Comparison

PK vs AMLX Comparison

Compare PK & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Park Hotels & Resorts Inc.

PK

Park Hotels & Resorts Inc.

HOLD

Current Price

$11.10

Market Cap

2.1B

Sector

Real Estate

ML Signal

HOLD

Logo Amylyx Pharmaceuticals Inc.

AMLX

Amylyx Pharmaceuticals Inc.

HOLD

Current Price

$17.77

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PK
AMLX
Founded
1946
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.8B
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
PK
AMLX
Price
$11.10
$17.77
Analyst Decision
Hold
Strong Buy
Analyst Count
10
9
Target Price
$11.10
$20.11
AVG Volume (30 Days)
3.4M
1.0M
Earning Date
04-30-2026
05-07-2026
Dividend Yield
8.82%
N/A
EPS Growth
N/A
65.46
EPS
N/A
N/A
Revenue
$2,791,000,000.00
$380,786,000.00
Revenue This Year
$2.48
N/A
Revenue Next Year
$2.72
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2.35
1612.94
52 Week Low
$9.51
$4.41
52 Week High
$12.39
$17.49

Technical Indicators

Market Signals
Indicator
PK
AMLX
Relative Strength Index (RSI) 55.46 68.37
Support Level $10.07 $13.19
Resistance Level $11.77 N/A
Average True Range (ATR) 0.31 0.91
MACD 0.10 0.28
Stochastic Oscillator 68.63 97.08

Price Performance

Historical Comparison
PK
AMLX

About PK Park Hotels & Resorts Inc.

Park Hotels & Resorts owns upper-upscale and luxury hotels, with 21,042 rooms across 33 hotels in the United States. Park also has interests through joint ventures in another 1,712 rooms in two US hotels. Park was spun out of Hilton Worldwide Holdings at the start of 2017, so most of its hotels are still under the Hilton brand. The company has sold all its international hotels and many of its lower-quality US hotels to focus on high-quality assets in domestic gateway markets.

About AMLX Amylyx Pharmaceuticals Inc.

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.

Share on Social Networks: